
The University Hospital Vall d'Hebron is highly specialised in rare diseases at regional, national, and international levels, with its incorporation as a full member of 20 of the 24 European Reference Networks (ERNs). The scientific direction of ERN-EuroBloodNet (www.eurobloodnet.eu), the ERN dedicated to Rare Haematological Diseases (RHD), is led by Dr Mañú Pereira, Head of the Rare Anemia Disorders Research Laboratory within the Cancer y Enfermedades Hematológicas Infantiles group.
Within ERN-EuroBloodNet, and in alignment with its strategic objectives, the team leads several European-level initiatives in rare haematological diseases and actively contributes to ERDERA (European Rare Disease Research Alliance), the Horison Europe partnership aiming to align and strengthen rare disease research across Europe. Through ERDERA, the group contributes to the integration of clinical expertise, research infrastructures, and data-driven approaches to improve diagnosis, treatment, and outcomes for patients with rare diseases.
The Rare Anaemia Disorders European Epidemiological Platform (RADeep) is an initiative endorsed by ERN-EuroBloodNet under the framework of the European Blood Disorders Platform (ENROL), the ERN-EuroBloodNet umbrella platform officially endorsed by the European Hematology Association (EHA) for European patient registries in rare haematological diseases. RADeep supports the prospective and longitudinal standardised collection of data from patients affected by rare anaemia disorders (RADs) at the European level, maximising public benefit by avoiding data fragmentation and promoting interoperability standards for patient registries. Its main objective is to enable epidemiological surveillance and disease burden assessment of RADs in the European Union, while fostering data-driven research using real-world data (RWD).
In this context, we are looking for a dedicated and detail-oriented Senior Scientific Coordinator to join our team. This position combines key account management responsibilities for the RADeep real-world data registry with the coordination of medical device development within a European Union–funded research project, requiring close interaction with clinical, technical, regulatory, and industry stakeholders.
University degree in area of biosciences (e.g. Pharmacy, Biomedicine, Bioengineering)
English (B2). We are working at European level and have frequent meetings in English
MSc / PhD
French or Italian language
At least 2 years of experience in scientific project management and coordination, preferably within academia, biotech, or pharmaceutical settings
Excellent communication skills and ability to work in a multidisciplinary team
Experience with scientific writing and project management in the field of rare diseases
Experience coordinating projects related to medical device technologies
Maintain long-term, trust-based relationships with key accounts, ensuring alignment with registries governance and scientific objectives.
Coordination of strategic meetings with our main stakeholders.
Support the positioning of the registries as a qualified source of real-world data for research, regulatory, and post-marketing purposes.
Contribute to sustainability strategies, including collaborations with pharmaceutical companies and European initiatives
Prepare stakeholder-facing materials (reports, dashboards, presentations)
Write scientific proposals.
Represent the initiatives in meetings, workshops, and strategic discussions at European level
Coordinate the end-to-end development of a medical device within the EU project, from requirements definition to validation and deployment.
Act as the interface between clinical experts, data scientists, software developers, regulatory specialists, and project management
Labour conditions:
Full-time: 37,5 h/week.
Starting date: immediate.
Gross annual salary: Remuneration will depend on experience and skills. Salary ranges are consistent with our Collective Agreement pay scale.
ContractTechnical and scientific activities contract linked to the project activities.
Incorporation to Vall d’Hebron Research Institute (VHIR), a public sector institution that promotes and develops the biomedical research, innovation and teaching at Vall d'Hebron University Hospital (HUVH), the biggest hospital of Barcelona and the largest of Catalan Institute of Health (ICS).
A scientific environment of excellence, highly dynamic, where high-end biomedical projects are continuously developed.
Continuous learning and a wide range of responsibilities within a stimulating work environment.
Individual training opportunities.
Flexible working hours.
23 days of holidays + 9 personal days.
Flexible Remuneration Program (including dining checks, health insurance, transportation and more)
Corporate Benefits: platform through which you can obtain significant discounts on travel, culture, technology, gastronomy, sports... among many others.
Healthy Offering: choose from a variety of wellbeing focused activities to be the healthiest you.
International Mobility Support (Welcome Services): We aim to make your arrival in Barcelona smooth and pleasant by providing city information, guidance on required procedures, access to the International Welcome Desk, family recommendations, and support in finding accommodation
Deadline to apply: 15/06/2026
Pre-selection: Candidates are shortlisted based on their skills, qualifications, and relevant experience as outlined in their CVs.
Interviews: Meetings may be held with Talent Acquisition and/or the hiring manager.
Practical assessment: Depending on the role, candidates may complete a case study, technical task, presentation, or written exercise, on-site or remotely.
Checks: Education, references, and other job-related verifications may be carried out.
Job offer: The selected candidate receives a formal job offer upon successful completion of the process.
VHIR embraces Equality and Diversity. As reflected in our values we work toward ensuring inclusion and equal opportunity in recruitment, hiring, training, and management for all staff within the organization, regardless of gender, civil status, family status, sexual orientation, gender identity and expression, religion, age, functional diversity or ethnicity.

We are a public sector institution that promotes and develops the biomedical research, innovation and teaching at Vall d'Hebron University Hospital, the hospital of Barcelona and the largest of Catalan Institute of Health (ICS). The members of our Board of Trustees are the Catalan Ministry of Health, the Catalan Ministry of Economy and Knowledge (we are a CERCA center), Vall d'Hebron University Hospital, Bank of blood and tissues, the Autonomous University of Barcelona (UAB), of which we are an accredited research institute, and the Vall d'Hebron Institute of Oncology (VHIO), which together with VHIR is part of Accredited Institute of Campus Vall d’Hebron Institute by the Institute of Health Carlos III (ISCIII).
Since its creation in 1994, VHIR works to find solutions to the health problems of society, and contribute to spread them around the world. In more than 20 years we have achieved leadership in biomedical research at hospitals in our country, and we want to be recognised in 2020 as an excellent and competitive European Institute leader in clinical and traslational research linked to a university hospital.
In our institute are working more than 1,300 people, of which over 1,200 doing research and others, around 100, help to do it or transfer it to the society once made, whether in the form of projects, technology transfer and innovation, communication or fundraising, among others.
The best of our institution and its research staff is doing research to solve people’s health problems. Our task is not only basic or translational, we are leaders in clinical research. We have the beds of the hospital separated in less than 50 meters of laboratories and our patients will benefit from our research. In this we believe, and our efforts are focused on it. This is understood by industry leaders who are committed to our hospital, making it a world reference for its first clinical trials.